相关实验视频

Updated: Jul 9, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

基因组分析揭示了更广泛的皮肤纤维细胞瘤原生菌的谱:对诊断和治疗的影响

Steven Christopher Smith¹, Kieran Sweeney², Mark G Evans²

¹Department of Pathology, Virginia Commonwealth University School of Medicine and VCU Massey Comprehensive Cancer Center, Richmond, Virginia.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

|February 16, 2025

概括

基因组分析有助于识别具有不寻常特征的纤维瘤皮质纤维瘤突起体 (FS-DFSP). 这种方法揭示了分子驱动因素,如TERT的活性化,有助于针对高级DFSP的向治疗.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
病理学病理学病理学

背景情况:

皮质纤维瘤突起 (DFSP) 是一种由PDGFB/PDGFD基因融合驱动的皮肤癌.
一些DFSP病例发展为纤维沙性DFSP (FS-DFSP),它可以转移并可能对氨酸激酶抑制剂产生反应.

研究的目的:

用全面的基因组分析来探索DFSP的临床,解剖和病理谱.
识别与FS-DFSP相关的基因组变化和分子特征.

主要方法:

从大型瘤测序实验室数据库中对具有PDGFB或PDGFD融合的瘤进行回顾性分析.
对组织学特征,临床数据,外基因组测序和副本数量变化的审查.
使用曼-惠特尼U和费舍尔精确测试进行统计分析.

主要成果:

发现了59例PDGFB/PDGFD融合病例 (55例是COL1A1::PDGFB,3例是EMILIN2::PDGFD,1例是COL1A2::PDGFB).
36%的瘤最初被错误分类,突出了诊断方面的挑战.
与经典的DFSP相比,FS-DFSPs显示了更多的基因组变异 (75%与23.8%相比),更高的瘤突变负担,并增加了TERT mRNA表达.

结论:

综合的基因组分析对于识别FS-DFSP,特别是那些具有异常表现的人来说是有价值的.
基因组分析有助于识别DFSP进展的潜在分子驱动因素,例如TERT重新激活.
这些发现支持使用基因组数据指导针对DFSP的向治疗,特别是高级或转移的形式.

关键词:

这是PDGFBB.据PDGFDD的说法,这是一个很大的问题.皮肤纤维细胞瘤突起性肌肉纤维细胞瘤这是一种纤维状瘤.这是下一代测序.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...